Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India · Delayed Price · Currency is INR 89.22
-1.45 (-1.60%)
Jul 25, 2025, 3:29 PM IST
Mangalam Drugs & Organics Revenue
In the fiscal year ending March 31, 2025, Mangalam Drugs & Organics had annual revenue of 3.18B INR, down -13.55%. Mangalam Drugs & Organics had revenue of 727.77M in the quarter ending March 31, 2025, a decrease of -28.61%.
Revenue
3.18B
Revenue Growth
-13.55%
P/S Ratio
0.44
Revenue / Employee
7.35M
Employees
432
Market Cap
1.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | 3.80B | 976.24M | 34.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |